Analyzing Current Therapies for Well-Differentiated Grade 3 Neuroendocrine Tumors

Panelists discuss how treatment selection for well-differentiated grade 3 neuroendocrine tumors requires careful consideration of factors including Ki-67 index, tumor biology, and disease progression rate to determine whether platinum-based chemotherapy or targeted therapies are most appropriate.